CD8A and hemophagocytic syndrome: Notably, by blocking cytokine signaling with ruxolitinib, we could sensitize CD8+ T cells to dexamethasone-induced apoptosis in vitro and with combination therapy significantly reducing tissue immunopathology and HLH disease manifestations in vivo (42).